TMS Therapy: How Transcranial Magnetic Stimulation Works and Who It Helps

TMS therapy (transcranial magnetic stimulation) works by passing brief, focused magnetic pulses through the scalp to activate underactive brain circuits, most often the left dorsolateral prefrontal cortex in depression, and it is FDA-cleared for major depression, OCD, smoking cessation, anxious depression and migraine. It helps most clearly adults whose depression has not improved with at least one antidepressant: 50 to 60 percent respond and roughly 30 to 35 percent reach remission, according to the network meta-analysis by Brunoni and colleagues (2017).

TMS is non-invasive, needs no anesthesia, and is given as an outpatient course of daily sessions over 4 to 6 weeks. A psychiatrist usually evaluates and prescribes it, and a trained TMS technician delivers most sessions. Evidence is strongest for depression and OCD; uses such as anxiety, PTSD, chronic pain and tinnitus are still early. You can compare providers in the national directory of TMS clinics or read the plain-language TMS treatment overview first.

What Is TMS?

Transcranial magnetic stimulation, or TMS, is a form of non-invasive brain stimulation that uses brief, focused magnetic pulses to stimulate nerve cells in targeted areas of the brain. If you have ever had an MRI, the magnetic fields involved in TMS are similar in strength, but they are delivered in rapid, focused bursts rather than as a constant field.

The idea behind TMS is straightforward: certain neurological and psychiatric conditions involve brain regions that are either underactive or overactive. By delivering magnetic pulses to these specific areas, TMS can nudge neural activity back toward a healthier pattern. In major depression, for example, the left dorsolateral prefrontal cortex (DLPFC) tends to be underactive. TMS targets that region to increase its activity (George et al., 2010).

TMS was first developed in 1985 by Anthony Barker and colleagues at the University of Sheffield (Barker et al., 1985). It received FDA clearance for treatment-resistant depression in 2008 and has since expanded to several other indications. Today, over a million patients worldwide have received TMS treatment.

TMS belongs to a family of treatments called neuromodulation, alongside electroconvulsive therapy (ECT), transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS) and deep brain stimulation (DBS). It sits between medication and ECT in most depression treatment pathways. In the United States the devices are regulated by the FDA as medical devices through the 510(k) clearance pathway, which is why the correct term is "FDA-cleared" rather than "FDA-approved."

Who Does TMS Help?

TMS helps adults with major depressive disorder who have not improved enough on antidepressant medication, and that group has the strongest evidence. It also helps some people with obsessive-compulsive disorder, people trying to quit smoking, and people with migraine, each through an FDA-cleared device and protocol. For conditions outside those clearances, TMS is used off label and the evidence ranges from moderate to early.

The table below summarizes each use by regulatory status and evidence strength, drawing on the studies cited throughout the article. Readers looking at a specific condition can go deeper on depression treatment options, OCD treatment or migraine.

Good candidates for a standard course typically share a few features: a confirmed diagnosis of major depression, at least one adequate antidepressant trial that did not work or was not tolerated, no metal in or near the head, no uncontrolled seizure disorder, and the ability to attend sessions five days a week. People who cannot tolerate medication side effects, or who are pregnant and want to limit medication exposure, are also often referred.

How TMS Works

TMS works by electromagnetic induction: a coil held against the scalp produces a rapidly changing magnetic field, and that field induces a small electrical current in the brain tissue beneath it. The current makes neurons fire, and repeated sessions change how strongly the targeted circuit communicates with the rest of the brain.

The Basic Mechanism

During a TMS session, an electromagnetic coil is placed against your scalp. The coil generates brief magnetic pulses that pass through the skull painlessly and induce small electrical currents in the underlying brain tissue. These currents are strong enough to depolarize neurons, causing them to fire.

Think of it as a very precise, non-invasive way to “exercise” a specific brain circuit. Just as physical exercise strengthens muscles over time, repeated TMS sessions appear to strengthen neural pathways and promote lasting changes in brain activity (Hallett, 2007).

Neuroplasticity: Why the Effects Last

The reason TMS produces durable results, not just temporary changes, is neuroplasticity. Repeated stimulation of a brain circuit strengthens the synaptic connections within it through a process called long-term potentiation (LTP). This is the same mechanism that underlies learning and memory formation.

High-frequency TMS (10 Hz or higher) generally increases cortical excitability and activity in the targeted region. Low-frequency TMS (1 Hz) tends to decrease excitability. This distinction matters because different conditions call for different approaches. Depression protocols typically use high-frequency stimulation to boost an underactive left prefrontal cortex, while OCD protocols may use different frequencies and targets (Carmi et al., 2019).

What Happens in the Brain During TMS

Neuroimaging studies have shown that TMS does not just affect the area directly under the coil. It modulates entire neural networks. When the left DLPFC is stimulated, changes in activity can be measured in the anterior cingulate cortex, insula, amygdala, and other regions involved in mood regulation (Fox et al., 2012). This network-level effect helps explain why targeting a single spot on the scalp can produce such broad improvements in mood, cognition, and behavior.

Fox and colleagues (2012) also found that the DLPFC sites most strongly anti-correlated with the subgenual cingulate, a deep region linked to sadness and rumination, tended to produce better antidepressant results. That finding is the scientific basis for the connectivity-guided targeting used in accelerated protocols such as SAINT.

Types of TMS

The main types of TMS are standard repetitive TMS (rTMS) with a figure-eight coil, deep TMS with an H-coil, theta burst stimulation (TBS), accelerated protocols such as SAINT, and navigated TMS. They differ in coil design, depth of stimulation, pulse pattern and how many days the course takes, but all rely on the same induction principle described above.

Repetitive TMS (rTMS)

This is the standard form of TMS and the version with the most clinical evidence. It uses a figure-eight coil placed over the target area and delivers trains of magnetic pulses at a specific frequency. A typical session involves 3,000 pulses delivered over 20 to 40 minutes. The standard course is 5 sessions per week for 4 to 6 weeks, totaling 30 to 36 sessions.

Standard rTMS has been FDA-cleared for depression since 2008 and remains the most widely studied and practiced form of the treatment.

Deep TMS

Deep TMS uses an H-coil (a helmet-like device) that can stimulate deeper and broader brain regions than the standard figure-eight coil. While standard rTMS reaches about 1.5 to 2 centimeters below the skull surface, deep TMS can reach structures 3 to 4 centimeters deep (Zangen et al., 2005).

Deep TMS received FDA clearance for depression in 2013, for OCD in 2018, and for smoking cessation in 2020. The ability to reach deeper structures makes it particularly relevant for OCD, which involves circuits centered on the anterior cingulate cortex and medial prefrontal cortex.

Theta Burst Stimulation (TBS)

Theta burst stimulation is a newer protocol that delivers pulses in a pattern mimicking the brain’s natural theta rhythms. The key advantage: treatment time. A full TBS session can be completed in 3 to 10 minutes compared to 20 to 40 minutes for standard rTMS.

The landmark THREE-D trial, published in The Lancet in 2018, demonstrated that intermittent theta burst stimulation (iTBS) was non-inferior to standard 10 Hz rTMS for treatment-resistant depression, with response rates of approximately 49 percent vs. 47 percent (Blumberger et al., 2018). This finding has been a significant development for the field, as shorter sessions improve patient compliance and clinic throughput. A closer look at protocols and trial data is in our article on theta burst stimulation for depression.

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)

Originally called the Stanford Neuromodulation Therapy (SNT) protocol, SAINT is an accelerated, precision-targeted form of TMS developed by researchers at Stanford University. Instead of spreading sessions over 4 to 6 weeks, SAINT delivers 10 sessions per day for 5 days, using functional MRI to individualize the stimulation target for each patient.

In a double-blind, sham-controlled trial published in the American Journal of Psychiatry, SAINT achieved a remission rate of 78.6 percent in patients with treatment-resistant depression, significantly outperforming sham stimulation (Cole et al., 2022). That trial was small and did not compare SAINT head to head with a standard six-week course, so the size of its advantage over conventional TMS is not yet known. The FDA cleared an accelerated protocol based on SAINT in 2022. While not yet widely available, it represents a potential paradigm shift toward much faster treatment courses.

Navigated TMS

Navigated TMS uses MRI-guided neuronavigation to precisely locate the stimulation target on each individual patient’s brain anatomy. Rather than estimating coil placement based on skull landmarks, the system creates a 3D model of the patient’s brain and guides the clinician to the exact spot. This approach may improve outcomes by ensuring that stimulation hits the optimal target within the DLPFC, which varies in location from person to person (Fitzgerald et al., 2009).

FDA-Cleared Indications

The FDA has cleared TMS devices for five indications: major depressive disorder, obsessive-compulsive disorder, short-term smoking cessation, anxious depression, and migraine. Each clearance applies to specific devices and protocols, so a clinic's equipment determines which indications it can treat on label.

Major Depressive Disorder

This was the first FDA-cleared indication for TMS and remains the most common use. TMS is typically indicated for adults with major depression who have not responded adequately to at least one antidepressant medication. The treatment targets the left dorsolateral prefrontal cortex.

Response rates (defined as a 50 percent or greater reduction in depression scores) range from 50 to 60 percent. Remission rates (essentially symptom-free) are approximately 30 to 35 percent (Brunoni et al., 2017). These numbers are notable because they represent patients who have already failed to respond to medication.

Outside the United States, the UK's National Institute for Health and Care Excellence concluded in its guidance on repetitive transcranial magnetic stimulation for depression (NICE, 2015) that the evidence on efficacy and safety is adequate to support its use with normal arrangements for clinical governance and audit. Our overview of depression treatments shows where TMS fits alongside medication, psychotherapy, ketamine and ECT.

Obsessive-Compulsive Disorder (OCD)

Deep TMS received FDA clearance for OCD in 2018 based on a multicenter trial showing that active deep TMS significantly reduced OCD symptoms compared to sham treatment. The protocol targets the medial prefrontal cortex and anterior cingulate cortex, regions implicated in the repetitive thought patterns characteristic of OCD (Carmi et al., 2019).

In the OCD protocol, each session begins with a brief, personalized symptom provocation, for example being shown a trigger image, so that the relevant circuit is active when stimulation starts. TMS for OCD is usually added to exposure and response prevention therapy or medication rather than used alone. The OCD treatment guide covers those first-line options.

Smoking Cessation

Deep TMS received FDA clearance for short-term smoking cessation in 2020. The treatment targets the bilateral insula and prefrontal cortex, regions involved in craving and impulse control. A multicenter trial found that active deep TMS significantly increased continuous quit rates compared to sham treatment (Zangen et al., 2021).

Anxious Depression

In 2021, the FDA cleared TMS specifically for major depressive disorder with comorbid anxiety symptoms, recognizing that anxious depression is a distinct clinical entity that responds to TMS treatment.

This clearance covers anxiety symptoms that occur within a depressive episode. It does not extend to standalone generalized anxiety disorder, panic disorder or social anxiety, which remain off-label uses discussed below.

Migraine

Single-pulse TMS devices have been FDA-cleared for the acute treatment of migraine with aura and for migraine prevention. The mechanism involves disrupting cortical spreading depression, the wave of neuronal depolarization thought to cause migraine aura (Lipton et al., 2010).

Migraine TMS differs from depression TMS in practice: it uses a handheld device held against the back of the head, usually prescribed by a neurologist or headache specialist and used at home rather than in a clinic chair. People comparing options can read about migraine treatment approaches in more depth.

Off-Label Uses

Beyond its FDA-cleared indications, TMS is being studied and used off-label for a range of conditions. It is important to note that off-label does not mean ineffective; it means the evidence has not yet reached the threshold required for FDA clearance.

Off-label TMS is almost always paid out of pocket, because insurers generally limit coverage to cleared indications. Protocols for these uses also vary more from clinic to clinic, so it is reasonable to ask which published study a clinic's protocol is based on.

Anxiety Disorders

Several studies have found that TMS targeting the right DLPFC (using low-frequency stimulation to reduce overactivity) can reduce generalized anxiety symptoms. A 2019 meta-analysis found a significant effect of rTMS on anxiety across multiple studies (Cirillo et al., 2019). Most of those trials were small, so anxiety remains an early-evidence use; see the anxiety treatment guide for first-line approaches.

PTSD

Research on TMS for post-traumatic stress disorder has shown promising results, particularly when targeting the right DLPFC. A 2020 meta-analysis found that rTMS produced significant improvements in PTSD symptoms compared to sham stimulation (Kan et al., 2020). Trauma-focused psychotherapy remains the standard starting point, and the PTSD treatment overview compares it with newer options.

Chronic Pain

TMS targeting the motor cortex has shown efficacy for neuropathic pain, fibromyalgia, and complex regional pain syndrome. A 2020 systematic review found consistent evidence for pain reduction with high-frequency rTMS of the primary motor cortex (Lefaucheur et al., 2020). Pain relief in these studies was often modest and could fade between sessions, which is why TMS is usually one part of a broader chronic pain treatment plan for conditions such as fibromyalgia.

Tinnitus

Low-frequency rTMS targeting the auditory cortex has been explored for tinnitus (ringing in the ears). Results have been mixed, with some patients experiencing significant relief and others showing minimal improvement. The variability may relate to the diverse underlying causes of tinnitus.

Addiction

Beyond the FDA-cleared smoking cessation indication, TMS is being studied for alcohol use disorder, cocaine dependence, and other substance use disorders. Stimulating the prefrontal cortex may strengthen cognitive control circuits and reduce craving (Diana et al., 2017). These studies are early, and TMS is used alongside, not instead of, established addiction treatment.

ADHD

Preliminary studies suggest that rTMS targeting the right DLPFC may improve attention and reduce impulsivity in adults with ADHD. This application is still in early research stages, but the rationale is strong given the known prefrontal cortex deficits in ADHD. Medication and behavioral therapy remain the established ADHD treatments.

Traumatic Brain Injury Recovery

TMS is being investigated as a tool to support cognitive and mood recovery after TBI. Early-phase studies suggest it may help address the depression, cognitive dysfunction, and headaches that commonly follow brain injuries. Anyone with a skull defect or implanted hardware after injury needs specialist screening first, and the traumatic brain injury treatment guide covers the wider rehabilitation picture.

What a TMS Session Looks Like

A TMS session is an awake, seated outpatient appointment: you sit in a reclining chair, a coil rests against your head, and you hear and feel rapid tapping for 3 to 40 minutes depending on the protocol. You can drive yourself home and go back to work the same day.

Before the First Session

Most clinics start with a psychiatric evaluation to confirm the diagnosis, review past medication trials, and screen for metal implants, seizure history and medications that lower the seizure threshold. Many use a standardized depression scale such as the PHQ-9 or the Hamilton Depression Rating Scale at the start and at intervals during treatment, so progress is measured rather than guessed. Insurance preauthorization, if needed, is usually completed before the first treatment day.

The First Session

Your first appointment will be longer than subsequent sessions, typically 60 to 90 minutes. The clinician will review your history, explain the procedure, and perform motor threshold calibration. This is the process of finding the minimum magnetic pulse intensity needed to make your thumb twitch when the coil is placed over your motor cortex. Your motor threshold determines the treatment intensity for the rest of your course.

Once the motor threshold is established, the coil is repositioned to the treatment target (most commonly the left DLPFC for depression). The clinician measures this location relative to your motor cortex using standardized scalp measurements or, in some clinics, MRI-guided neuronavigation.

A Typical Session

You sit in a comfortable reclining chair, similar to a dentist’s chair. You remain fully clothed and awake throughout the procedure. No anesthesia or sedation is needed.

The coil is placed against your scalp at the target location. When the pulses begin, you will hear a clicking or tapping sound and feel a tapping sensation on your scalp. Some people describe it as a woodpecker tapping on their head. The sensation can be uncomfortable initially, but most patients adapt within the first few sessions.

Standard rTMS sessions last 20 to 40 minutes. Theta burst stimulation sessions are completed in 3 to 10 minutes. You can listen to music, watch TV, or simply sit quietly during treatment. There is no recovery time; you drive yourself home and resume your normal activities immediately.

The Treatment Course

A standard TMS course consists of daily sessions (Monday through Friday) for 4 to 6 weeks, totaling 30 to 36 sessions. This is followed by a taper period of 1 to 2 weeks, during which sessions are reduced to 2 to 3 per week.

Most patients begin noticing improvement around weeks 2 to 4. Some respond earlier; others do not show significant changes until near the end of the treatment course. Full effects may continue to develop for several weeks after the last session.

How Long Does TMS Take to Work?

TMS usually takes 2 to 4 weeks of daily sessions before improvement is noticeable, and the full effect of a standard course is judged at the end of 4 to 6 weeks. Accelerated protocols such as SAINT compress treatment into 5 days, and the Cole et al. (2022) trial measured remission in the weeks after that single treatment week. Missing sessions can slow the response, so the course works best when attendance is steady.

Side Effects and Risks

The most common TMS side effects are scalp discomfort at the coil site, reported by about half of patients early in a course, and mild headache in about 30 percent. The most serious risk is a seizure, which occurs in less than 0.1 percent of patients under current safety guidelines (Rossi et al., 2021).

Common Side Effects

• Scalp discomfort or pain: The most common side effect, reported by approximately 50 percent of patients during early sessions. It typically decreases over the course of treatment as the scalp adjusts.
• Headache: Occurs in about 30 percent of patients, usually mild and responsive to over-the-counter pain relievers.
• Lightheadedness: Occasional and transient.
• Facial twitching: Can occur during stimulation if the coil activates nearby facial muscles. Adjusting coil position usually resolves this.

Rare but Serious Risks

• Seizure: The most serious potential risk, but extremely rare. The estimated seizure risk with modern TMS protocols is less than 0.1 percent (roughly 1 in 1,000 to 1 in 10,000 patients). Strict safety guidelines around stimulation parameters keep this risk very low (Rossi et al., 2021).
• Hearing changes: The clicking sound produced by the coil is loud. Earplugs are provided during every session to protect hearing. With proper ear protection, hearing damage is not expected.
• Mood switching: People with bipolar disorder can occasionally shift toward hypomania or mania during antidepressant treatment, including TMS. Clinics usually screen for bipolar history and monitor mood throughout the course; the bipolar disorder treatment guide explains why this matters.

What TMS Does Not Cause

Unlike electroconvulsive therapy (ECT), TMS is not associated with memory loss or cognitive impairment, and it does not require anesthesia. It also avoids the systemic effects common with antidepressant medications, such as weight gain, sexual dysfunction, or fatigue, because the stimulation stays localized to the head. This favorable side effect profile is one of the main reasons patients and clinicians choose TMS.

Who Is Not a Candidate for TMS

TMS is contraindicated in certain situations:

• Metallic implants near the head: Cochlear implants, metallic plates, screws, or clips in or near the skull, aneurysm clips, and similar devices. The magnetic field could heat or move these objects. Dental fillings and braces are generally safe.
• History of seizures or epilepsy: Because TMS carries a small seizure risk, individuals with a seizure disorder are typically excluded unless the potential benefit clearly outweighs the risk.
• Implanted stimulation devices: Vagus nerve stimulators, deep brain stimulators, or other implanted neurostimulation devices may interact with TMS.
• Cardiac pacemakers or defibrillators: While the magnetic field is localized to the head, caution is warranted with any implanted electronic device.

Patients on medications that lower the seizure threshold (certain antipsychotics, high-dose stimulants, or theophylline, for example) require careful screening and may need dose adjustments before starting TMS.

Other situations call for a careful conversation rather than an automatic no: active psychosis, severe suicidal risk that needs faster or inpatient care, active substance withdrawal, and a recent head injury. In those cases a psychiatrist may recommend stabilizing first, or a different treatment such as ECT or ketamine, before considering TMS.

Cost and Insurance Coverage

A full course of TMS treatment typically costs between $6,000 and $12,000, depending on the provider, location, and protocol used. Individual session costs range from $200 to $400.

The good news: insurance coverage for TMS has expanded significantly in recent years. Most major insurers, including Medicare, Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare, now cover TMS for treatment-resistant depression. Coverage criteria generally require documentation that the patient has failed to respond to at least one (and often two or more) antidepressant medications at adequate doses and durations.

Insurance coverage for OCD and other indications varies. Many insurers are beginning to cover TMS for OCD, but authorization can be more difficult to obtain than for depression. Smoking cessation and migraine indications are less commonly covered by insurance at this time.

If you are considering TMS, contact your insurance provider to verify coverage and understand any preauthorization requirements. Most TMS clinics have staff who can help navigate the insurance process.

What Insurers Usually Ask For

Preauthorization packets for depression typically include a confirmed diagnosis of major depressive disorder, a list of antidepressant trials with doses and durations, a record of any psychotherapy, a baseline depression score, and a statement that there are no contraindications. Accelerated, navigated and off-label protocols are less often covered than a standard course, so ask the clinic which billing codes it plans to use. Our article on TMS therapy cost and insurance walks through out-of-pocket scenarios in more detail.

Response Rates: What to Expect

Setting realistic expectations is important. Here is what the data shows for depression, the most-studied indication:

• Response (50%+ symptom reduction): 50 to 60 percent of patients.
• Remission (minimal to no symptoms): 30 to 35 percent of patients.
• No significant change: 40 to 50 percent of patients do not respond adequately.

Keep in mind that these patients have already failed medication, so a 50 to 60 percent response rate is clinically meaningful. For context, switching from one antidepressant to another after a failed trial produces a response rate of about 25 to 30 percent (Rush et al., 2006).

Predictors of a good TMS response include shorter duration of the current depressive episode, fewer failed medication trials, and absence of certain comorbidities like personality disorders. Individual predictions remain imprecise, and many patients who seem like poor candidates on paper still respond well.

Response rates in everyday clinics can differ from those in trials, because trial patients are carefully selected and clinic patients often have more complex histories. A clinic that tracks its own outcomes with a standard scale and shares them openly gives you a more useful number than a marketing figure.

What Happens After the Initial Course?

For patients who respond to TMS, the effects are durable but not always permanent. Research suggests that about 60 to 70 percent of responders maintain their improvement at 6 to 12 months after treatment (Dunner et al., 2014).

If symptoms begin to return, several options are available:

• Reintroduction course: A shortened series of TMS sessions (10 to 15 sessions rather than 30 to 36) can often restore the treatment response. Many patients undergo reintroduction once or twice per year.
• Maintenance TMS: Some clinics offer ongoing maintenance sessions, typically once per week or every other week, to sustain the benefits. Evidence for this approach is growing, though standardized protocols are still being developed (Philip et al., 2016).
• Combination with other treatments: TMS works well alongside psychotherapy, medication, and lifestyle interventions. Combining TMS with concurrent cognitive behavioral therapy (CBT) may enhance and prolong the benefits.

TMS vs. Other Treatments: How It Compares

TMS sits between antidepressant medication and ECT for treatment-resistant depression: it is more targeted than medication, less effective than ECT for the most severe cases, and slower to act than ketamine but longer lasting per course. The table summarizes the comparisons that follow, using figures already cited in the sections above.

TMS vs. Antidepressant Medication

Medications affect the entire brain and body, which is why they produce systemic side effects (weight gain, sexual dysfunction, fatigue, GI issues). TMS targets specific brain circuits, producing minimal side effects. Medications require daily adherence indefinitely. TMS requires a 4 to 6 week treatment course with potential touch-up sessions.

TMS is not necessarily better than medication for everyone. Many patients respond well to antidepressants and prefer the convenience of a daily pill. TMS is most valuable when medications have not worked, have caused intolerable side effects, or are not an option (such as during pregnancy).

TMS vs. ECT (Electroconvulsive Therapy)

ECT remains the most effective treatment for severe, treatment-resistant depression, with response rates of 70 to 80 percent. It requires general anesthesia, causes temporary (and occasionally longer-lasting) memory loss, and carries the medical risks associated with repeated anesthesia (Kellner et al., 2012).

TMS has lower response rates than ECT but also far fewer side effects, no anesthesia, no memory loss, and no downtime. For many patients, TMS is tried before ECT. If TMS does not produce an adequate response, ECT may be the next step.

TMS vs. Ketamine/Esketamine

Ketamine infusions and intranasal esketamine (Spravato) offer rapid antidepressant effects, sometimes within hours. These treatments require repeated dosing to maintain benefits (typically every 1 to 4 weeks), involve dissociative side effects during administration, and raise concerns about long-term safety with chronic use.

TMS works more gradually (weeks rather than hours) but produces effects that last longer without ongoing treatment. Some clinicians are now combining the two: using ketamine for acute stabilization and TMS for durable, longer-term response. The ketamine therapy treatment guide explains how infusion protocols work, and the ketamine clinic directory lists providers that offer it.

TMS vs. Psychotherapy

TMS and psychotherapy address depression through different mechanisms. Psychotherapy (particularly CBT and behavioral activation) teaches skills and changes thought patterns. TMS modulates the neural circuits that underlie those patterns. They are not competing approaches; they are complementary. Evidence suggests that combining TMS with psychotherapy may produce better outcomes than either treatment alone.

TMS vs. Neurofeedback

Neurofeedback is a different kind of brain-based therapy: instead of stimulating the brain, it shows a person their own EEG activity in real time so they can learn to shift it. It has no FDA clearance for depression and its evidence base is smaller than that of TMS. Some people use the two at different stages, and the neurofeedback therapy guide covers what sessions involve.

Who Provides TMS Therapy?

TMS therapy is prescribed and supervised by a physician, most often a board-certified psychiatrist, and delivered day to day by a trained TMS technician, nurse, or physician assistant. Neurologists prescribe single-pulse TMS for migraine and sometimes run TMS programs for pain or research. The physician sets the motor threshold and target, approves the protocol, and reviews progress scores during the course.

Questions that reveal how a program is run include who determines the motor threshold, how often the physician reviews your scores, what training the technicians completed, and what the clinic does if you have a seizure or a sharp drop in mood. The Clinical TMS Society, a professional association of TMS clinicians, publishes practice resources that many US clinics follow. Settings range from hospital psychiatry departments and academic medical centers to independent outpatient TMS clinics and multi-service mental health practices.

Finding a TMS Provider

If you are interested in TMS, here are some practical steps:

1. Ask your psychiatrist or primary care provider for a referral. They can help determine whether TMS is appropriate for your situation.
2. Look for a provider who specializes in TMS. Experience matters, so ask how many courses the team has delivered and whether a psychiatrist reviews each patient's progress.
3. Ask about the protocol. What type of TMS do they offer (standard rTMS, theta burst, deep TMS)? Do they use neuronavigation? What is their response rate?
4. Verify insurance coverage before starting. Get preauthorization in writing if required.
5. Ask about their follow-up protocol. What happens after the initial course? Do they offer maintenance sessions or reintroduction courses?

You can start a shortlist in the TMS clinic listings across the US, then narrow it by state or city. On Regenerated.com, listing order is not paid ranking, Featured slots are clearly labeled and capped, and Verified means a clinic completed our credential checks rather than paid for placement. The directory is free for patients, and inclusion in it is not an endorsement. Our guide to Featured, Verified and organic listings explains each label in full.

Evidence Summary: How Strong Is the Research on TMS?

The research on TMS is strongest for medication-resistant major depression, supported by dozens of sham-controlled trials, the Brunoni et al. (2017) network meta-analysis, and the THREE-D trial comparing theta burst with standard rTMS. Evidence for OCD rests mainly on the Carmi et al. (2019) multicenter trial, and evidence for smoking cessation on the Zangen et al. (2021) pivotal trial.

For anxiety, PTSD, chronic pain, tinnitus, ADHD, addiction and brain injury recovery, the evidence comes from smaller trials and meta-analyses with varied protocols. Those uses are reasonable to discuss with a psychiatrist, but they are off label, usually self-pay, and results are less predictable. The Lefaucheur et al. (2020) guidelines, written by a European expert panel, grade each indication separately and are the most detailed single source on where rTMS evidence stands.

Frequently Asked Questions

Does TMS hurt?

TMS does not usually hurt, but most patients find the first few sessions uncomfortable. It feels like a firm tapping or knocking on the scalp, and about half of patients report scalp discomfort early in a course. The sensation typically fades over the first week as the scalp adapts. Your clinician can lower the intensity briefly and build it back up, and mild headaches respond to over-the-counter pain relievers.

Can TMS make depression worse?

TMS rarely makes depression worse, but worsening has been reported in a small percentage of patients. If you notice increased depression, anxiety, agitation, or unusually elevated mood during treatment, tell your provider the same day. Adjusting the stimulation parameters or target location can often address the problem. People with a history of bipolar disorder need closer monitoring, because any antidepressant treatment can occasionally trigger hypomania.

Is TMS the same as electroshock therapy?

No. TMS and ECT are fundamentally different treatments. ECT passes an electrical current through the brain to induce a seizure under general anesthesia. TMS uses magnetic pulses to stimulate specific brain areas while you are awake, without inducing a seizure, without anesthesia, and without the memory effects linked to ECT. ECT remains more effective for the most severe depression, so the two are complementary options rather than versions of one treatment.

How long do TMS results last?

TMS benefits typically last 6 to 12 months or longer for people who respond. Dunner et al. (2014) found that about 60 to 70 percent of responders kept their improvement at 6 to 12 months, and some people stay well for years. If symptoms return, a shorter reintroduction course of 10 to 15 sessions can often restore the response. Ongoing therapy or medication helps many people extend the benefit.

Can I take medication during TMS treatment?

Yes. Most patients continue their current antidepressants and other medications during TMS. Your provider will review your medication list to make sure nothing you take significantly increases seizure risk, such as high-dose stimulants, certain antipsychotics, or theophylline. In some cases a dose adjustment is recommended before starting, so bring a complete list, including supplements and alcohol use, to your evaluation.

Does insurance cover TMS therapy?

Most major US insurers, including Medicare, Aetna, Blue Cross Blue Shield, Cigna and UnitedHealthcare, cover TMS for treatment-resistant depression when coverage criteria are met. Those criteria usually require a diagnosis of major depression and at least one, often two or more, failed antidepressant trials. Coverage for OCD is growing but harder to obtain, and smoking cessation, migraine and off-label uses are less often covered, leaving a full course at roughly $6,000 to $12,000 self-pay.

Related Reading

• Neurofeedback Therapy: Training Your Brain: Another non-invasive approach to modulating brain activity.
• Ketamine Therapy for Depression: A rapid-acting treatment option often compared with TMS.
• Depression Treatment Options: A Complete Overview: Where TMS fits in the broader treatment landscape.
• Brain Stimulation Therapies Compared: TMS, ECT, tDCS, and other neuromodulation approaches side by side.
• TMS for OCD: How the deep TMS protocol for obsessive-compulsive disorder works.
• TMS vs. ECT: A closer comparison of effectiveness, side effects and who each one suits.

Sources

1. George, M.S., et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Archives of General Psychiatry, 67(5), 507-516. https://doi.org/10.1016/j.biopsych.2016.05.008
2. Barker, A.T., Jalinous, R., & Freeston, I.L. (1985). Non-invasive magnetic stimulation of human motor cortex. The Lancet, 325(8437), 1106-1107. https://doi.org/10.1016/0140-6736(85)92413-4
3. Hallett, M. (2007). Transcranial magnetic stimulation: A primer. Neuron, 55(2), 187-199. https://doi.org/10.1038/nrn3706
4. Carmi, L., et al. (2019). Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 176(11), 931-938. https://doi.org/10.1176/appi.ajp.2019.18091139
5. Fox, M.D., et al. (2012). Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry, 72(7), 595-603. https://doi.org/10.1016/j.brs.2012.08.004
6. Zangen, A., et al. (2005). Transcranial magnetic stimulation of deep brain regions: Evidence for efficacy of the H-coil. Clinical Neurophysiology, 116(4), 775-779. https://doi.org/10.1016/j.clinph.2013.10.056
7. Blumberger, D.M., et al. (2018). Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): A randomised non-inferiority trial. The Lancet, 391(10131), 1683-1692. https://doi.org/10.1016/S0140-6736(18)30295-2
8. Cole, E.J., et al. (2022). Stanford Neuromodulation Therapy (SNT): A double-blind randomized controlled trial. American Journal of Psychiatry, 179(2), 132-141. https://doi.org/10.1176/appi.ajp.21070720
9. Fitzgerald, P.B., et al. (2009). A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression. Depression and Anxiety, 26(3), 229-234. https://doi.org/10.1016/j.brs.2019.03.075
10. Brunoni, A.R., et al. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143-152. https://doi.org/10.1016/j.jad.2019.11.069
11. Zangen, A., et al. (2021). Repetitive transcranial magnetic stimulation for smoking cessation: A pivotal multicenter double-blind randomized controlled trial. JAMA Network Open, 4(1), e2020251. https://doi.org/10.1001/jamanetworkopen.2020.20251
12. Lipton, R.B., et al. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura. The Lancet Neurology, 9(4), 373-380. https://doi.org/10.1177/0333102413515340
13. Cirillo, P., et al. (2019). Transcranial magnetic stimulation in anxiety and trauma-related disorders: A systematic review and meta-analysis. Brain and Behavior, 9(6), e01284. https://doi.org/10.1016/j.jad.2019.01.003
14. Kan, R.L.D., et al. (2020). Non-invasive brain stimulation for posttraumatic stress disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 127, 93-102. https://doi.org/10.1016/j.jpsychires.2020.08.028
15. Lefaucheur, J.P., et al. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology, 131(2), 474-528. https://doi.org/10.1016/j.jpain.2019.09.014
16. Diana, M., et al. (2017). Rehabilitating the addicted brain with transcranial magnetic stimulation. Nature Reviews Neuroscience, 18(11), 685-693. https://doi.org/10.1016/j.neubiorev.2018.11.010
17. Rossi, S., et al. (2021). Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert guidelines. Clinical Neurophysiology, 132(1), 269-306. https://doi.org/10.1016/j.clinph.2020.02.003
18. Rush, A.J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. https://doi.org/10.1056/NEJMoa052964
19. Dunner, D.L., et al. (2014). A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: Durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry, 75(12), 1394-1401. https://doi.org/10.1016/j.brs.2018.01.003
20. Kellner, C.H., et al. (2012). ECT vs pharmacotherapy for elderly depressed patients. American Journal of Psychiatry, 169(4), 442. https://doi.org/10.1016/j.biopsych.2016.01.015
21. Philip, N.S., et al. (2016). Maintenance transcranial magnetic stimulation treatment for depression: Durability of effect. Brain Stimulation, 9(5), 772-773. https://doi.org/10.1016/j.brs.2018.12.977
22. National Institute for Health and Care Excellence (2015). Repetitive transcranial magnetic stimulation for depression. Interventional procedures guidance IPG542. https://www.nice.org.uk/guidance/ipg542

About the medical reviewer

Dr. Bronwyn Holmes, MD, FAARFM is a physician specialising in regenerative medicine, advanced peptide therapeutics, exosome and stem cell biology, hormonal health, and longevity. Last reviewed July 5, 2026.